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Abstract
Background: Resection and replacement of the inferior vena cava to remove malignant disease is
a formidable procedure. The purpose of this review is to describe our experience with regard to
patient selection, operative technique, and early and late outcome.
Methods: The authors retrospectively reviewed a 12-year series of 11 patients; there were 10
males, with a mean age 57 ± 13 years (range 27–72) who underwent caval thrombectomy and/or
resection for primary (n = 9) or recurrent (n = 2) vena cava tumours. Tumour location and type,
clinical presentation, the segment of vena cava treated, graft patency, and tumour recurrence and
survival data were collected. Late follow-up data were available for all patients. Graft patency was
determined before hospital discharge and in follow-up by CT scan or ultrasonography. More than
80% of patients had symptoms from their caval involvement. The most common pathologic
diagnosis was renal cell carcinoma (n = 6), and hepatocarcinoma (n = 2). In all but 2 patients, inferior
vena cava surgical treatment was associated with multivisceral resection, including extended
nephrectomy (n = 5), resection of neoplastic mass (n = 3), major hepatic resection (n = 2), and
adrenal gland resection (n = 1). Prosthetic repair was performed in 5 patients (45%).
Results: There were no early deaths. Major complications occurred in 1 patient (9%). Mean length
of stay was 16 days. Late graft thrombosis or infection did not occur. The mean follow-up was 22.7
months (range 6–60). There have been no other late graft-related complications. All late deaths
were caused by the progression of malignant disease and the actuarial survival rate was 100% at 1
year. Mean survival was 31 months (median 15).
Conclusion: Aggressive surgical management may offer the only chance for cure or palliation for
patients with primary or secondary caval tumours. Our experience confirms that vena cava surgery
for tumours may be performed safely with low graft-related morbidity and good patency in carefully
selected patients.
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Background
Neoplastic caval involvement has traditionally been sus-
pected by the presenting symptoms of lower extremity
swelling and venous engorgement [1]. The widespread use
of preoperative CT scans has demonstrated that many
asymptomatic patients could have involvement of the
vena cava by tumour [2].
However, resection and replacement for malignant
involvement of the inferior vena cava (IVC) is generally
indicative of advanced disease, and has been performed
rarely because of the magnitude and risk of the operation;
nevertheless, in the absence of surgical resection, patient
survival is limited, because effective treatment alternatives
are few [2].
Experience with this type of operation at an individual
institution remains very limited [2-4]; indeed, most pub-
lications on the subject have been sporadic single-case
reports. In our experience, a variety of tumours were
encountered; partial resection of the caval wall, with
either primary or patch closure, has been reported to be
preferable to graft replacement because it is safer and eas-
ier to perform [2].
The aim of this retrospective analysis is to describe the
outcome of surgical treatment for IVC malignant involve-
ment in a series of 11 patients with extensive abdominal
tumours and to discuss our policy for IVC replacement.
Materials and methods
In the last 15-years, 11 resections of the IVC were carried
out to achieve excision of malignant or benign abdominal
tumours. Procedures involving lateral IVC resection, tran-
scaval removal of tumour thrombus, with or without car-
diopulmonary bypass (CPB) were included. The patient's
clinical presentation, the type and location of the tumour,
the segment of vena cava replaced, graft patency, and
tumour recurrence and survival were collected for all
patients [Tab. 1]. There were 10 men with a mean age of
57 ± 13 years (range, 27–72; median 60).
The indication for IVC resection was primary invasion by
adjacent primary (n = 8) or recurrent (n = 2) malignancy.
In the remaining patient, the indication was benign
tumour involvement. One patient received preoperative
adjuvant therapy in the form of radiation therapy.
Chest roentgenography, computed tomography (CT),
ultrasonography, or magnetic resonance imaging (MRI)
were used to exclude the presence of metastatic disease, to
assess local resectability of the tumour, and to assess the
extent of involvement and obstruction of the IVC [Fig. 1].
Early in our experience, vena cavography was used preop-
eratively to determine the degree of caval obstruction, and
to help plan the operation [Fig. 2]. At present, vena cavog-
raphy is used only if the venous anatomy is not shown
well by the other imaging studies. Involvement of the IVC
was classified as infrarenal (n = 7) or suprarenal (n = 2);
two patients (18%) had right heart involvement. Obstruc-
tion was partial in 8 cases (73%) and complete in 3
patients (27%).
If the tumour was found locally resectable, an extensive
medical evaluation of the patient was performed to assess
operative risk. Surgery was performed with extracorporeal
circulation in two cases because of right atrial involve-
ment. Abdominal surgical access was carried out through
a subcostal incision (n = 8) or through a midline incision
(n = 3). Complete gross tumour resection was achieved in
all patient following the main oncological principles (no
touch techniques and vessels legation at their origins).
Tumor thrombectomy alone was performed in 7 patients
(64%), 3 had reconstruction of the infrarenal IVC with
patch angioplasty (27%), and 1 patients (9%) had graft
replacement of the suprarenal IVC. Dacron grafts (Bard®-
Tempe, AZ-USA) were used in all patients with patch
reconstruction [Fig. 3], while PTFE (W.L. Gore and ass.®-
Table 1: Demographic data of 11 patients with IVC neoplastic involvement: Insubria experience
sex/age symptoms type of tumour IVC segment months: follow-up
M/66 lower limb oedema kidney infrarenal 60: dead
M/55 lower limb oedema kidney infrarenal 60: alive
M/58 lower limb oedema kidney infrarenal 12: dead
M/71 pneumonia-pulmonary 
embolism
kidney infrarenal 12: dead
M/60 lower limb oedema kidney infrarenal 24: dead
M/64 lower limb oedema hepatocarcinoma right heart involvement 12: dead
F/49 acute heart failure pelvic leiomyomatosis right heart involvement 12: alive
M/72 weight loss kidney infrarenal 6: alive
M/27 fatigue/weight loss testicular teratocarcinoma infrarenal 12: dead
M/60 pain/weight loss hepatocarcinoma suprarenal 12: alive
M/45 lower limb oedema adrenal gland suprarenal 6: aliveInternational Seminars in Surgical Oncology 2006, 3:19 http://www.issoonline.com/content/3/1/19
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Flagstaff, AZ-USA) was preferred for replacement. Long-
term prophylactic antibiotics were administered in all
patients; postoperatively, all patients started receiving
subcutaneous heparin or low-dose intravenous heparin
within 24 to 48 hours.
Tumour histology included renal cell carcinoma (n = 6),
hepatocarcinoma (n = 2), testicular teratocarcinoma (n =
1), pelvic leiomyomatosis (n = 1), and adrenal gland car-
inoma (n = 1). Graft patency was systematically assessed
in the early postoperative period and during follow-up by
one or more studies including vena cavography, CT scan
or ultrasonography. These same imaging studies were
used to determine the presence of recurrent or metastatic
disease. Adjuvant radiation or chemotherapy was given to
selected patients depending on the tumour type.
Results
More than 80% of the patients were initially seen with one
or more symptoms from their tumour, including lower
extremity oedema (n = 6; 55%), pain-weight loss and
fatigue (n = 4; 36%), and pneumonia following pulmo-
nary embolism (n = 1; 9%). In all patients, IVC resection
was associated with visceral resection, including extended
nephrectomy (n = 5), resection of retroperitoneal mass (n
= 3), major hepatic resection (n = 2), and excision of the
adrenal gland (n = 1). Negative tumour margins were
obtained in all patients. Median intraoperative transfu-
sion volume was 2 units of packed red blood cells (range
0–5 units). There were no perioperative deaths. One
patient had major complication: cardio-respiratory failure
developed in a 71-year male patient with myasthenia
gravis, and chronic obstructive pulmonary disease with
preoperative poor respiratory function. The remaining
patients (91%) recovered and were discharged unevent-
fully. The median hospital stay was 14 days (mean 16;
Preliminary cavography: caval involvement (arrow) from a  retroperitoneal mass (pelvic leiomyomatosis) Figure 2
Preliminary cavography: caval involvement (arrow) from a 
retroperitoneal mass (pelvic leiomyomatosis).
Preoperative CT-angiography shows a complete caval  obstruction (arrow) due to a tumoral mass of the right adre- nal gland (A); postoperative histology revealed a primary car- cinoma with kidney infiltration (B) Figure 1
Preoperative CT-angiography shows a complete caval 
obstruction (arrow) due to a tumoral mass of the right adre-
nal gland (A); postoperative histology revealed a primary car-
cinoma with kidney infiltration (B).International Seminars in Surgical Oncology 2006, 3:19 http://www.issoonline.com/content/3/1/19
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range, 6–32). There was no evidence of graft-related infec-
tion during the hospital stay or since discharge; CT scans
or duplex studies obtained before discharge demonstrated
patency of the IVC graft in all patients.
Follow-up ranged 6 to 60 months (mean, 22.7; median
12). There were no re-operations. Late deaths occurred
from regional or distant metastatic disease. Despite the
variety of malignancies, overall survival was calculated by
using Kaplan-Meier survival estimates with 95% confi-
dence intervals [Fig. 4]. One-year survival was 100%;
mean survival was 31 months (median 15, range 6–60).
Discussion
The role of IVC resection and replacement for the treat-
ment of malignant disease is limited to a small number of
select patients, and only few surgeons have focused on its
development [5,6]. In fact, data regarding the survival of
patients with primary or secondary caval malignancies is
sparse [6-9]. This series describing 11 patients who under-
went IVC resection for neoplasms with or without pros-
thetic replacement, is one of the largest to date.
In contrast to many previously published series, our expe-
rience includes patients with a variety of tumoral condi-
tions at different levels of the IVC [2-4]. Although there is
a trend toward improvement in survival in these patients,
and aggressive management could produce long-term sur-
vival, the diverse aetiology of cancers herein and the small
number of patients preclude conclusions regarding the
impact of these operations on survival. In addition,
replacement after IVC resection is controversial: however
in our experience, patients with extensive intraluminal
involvement, open thrombectomy alone or patch recon-
struction of the IVC did not carried the risk of late recur-
rence from the venous wall. If radical tumour resection
and caval replacement are to have any role, the operative
mortality and morbidity must be low, patients must be
carefully selected, and the grafts must be durable. The
operative mortality in our patients is low, given the mag-
nitude of the procedure, and is consistent with other
reports, with an estimated mean survival of 31 months for
patients with malignant disease. In comparison, median
survival without resection has been reported to be one
month for patients with primary retroperitoneal tumours
[2]. Thus, we advocate more widespread use of IVC resec-
tion; indeed, we believe that a multidisciplinary
approach, and careful evaluation and treatment of these
patients is a mandatory component for patient selection.
Procedures have been usually performed through an
abdominal incision; indeed, in agreement with previous
authors, we think that cardiopulmonary bypass (CPB) is
unnecessary unless the tumour extends significantly into
the atrium as occurred in two cases [10,11]. Surgical pro-
cedures could be performed with single or double-staged
procedures. CPB has been used to remove tumours and
thrombus in the IVC and right heart cavities with success;
nowadays, the single-stage caval and cardiac resection of
the tumour has been abandoned due to the high risk of
diaphragmatic lacerations [11]. In the presented cases, we
adopted a two-stage approach because the initial thoracic
allowed safe resection of the intracardiac tumour mass:
moreover operative time was shorter, despite the risks of a
second general anaesthesia, and could reduce the risk of
bleeding because of systemic heparinization required for
Kaplan-Meier analyses of the survival in 11 patients Figure 4
Kaplan-Meier analyses of the survival in 11 patients.
Postoperative findings: tumoral thrombus after complete sur- gical removal (A) Figure 3
Postoperative findings: tumoral thrombus after complete sur-
gical removal (A). Dacron patch angioplasty was used to 
repair IVC resection to achieve complete tumour excision 
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CPB. The slow growth of the tumour allows for a safe
interval between two major surgical procedures.
Caval involvement has traditionally been suspected by the
presenting symptoms of venous engorgement [1,4]. The
widespread use of preoperative CT scans has demon-
strated that many asymptomatic patients could have
involvement of the vena cava by tumour [2,3]. Preopera-
tive radiological investigation is critical for careful patient
selection and outcome: most patients are imaged with CT
scan to define the extent of the tumour and the presence
of metastatic disease. In our early experience, vena cavog-
raphy was routinely performed preoperatively; however,
we no longer routinely use this study but reserve it for
patients with suspected IVC occlusion or those with signs
or symptoms of venous insufficiency for whom the IVC is
not adequately imaged by CT scan or MRI. Considering
symptoms and signs, wide retroperitoneal resection
including a segment of the IVC disrupts pre-existing
venous channels and thus can reduce collateral venous
return. Our experience subverted previous evidence:
indeed, early or late postoperative symptoms of venous
obstruction were never observed, whereas preoperative
lower limb swelling disappeared after surgery with
thrombectomy and resection.
The presence of tumour thrombus into inferior vena cava
from abdominal cancers carries the threat of pulmonary
tumour embolus [12]. When this occurs, the outcome is
catastrophic; thus, some reports have advocated place-
ment of a suprarenal IVC filter before resection. However,
reports of tumour emboli during surgical resection for
malignant caval involvement are anecdotal [12]; therefore
we did not place caval filter in any of our patients, and
pulmonary embolism was never encountered in our expe-
rience.
Conclusion
We believe that aggressive surgical management may offer
the only chance for cure or palliation of symptoms in
select patients with primary or secondary tumours of the
IVC: patients with localized disease, no significant medi-
cal problems, and a good preoperative performance status
should be considered candidates for tumour resection.
To date, our clinical experience has been satisfactory. The
ability to safely accomplish caval resection without peri-
operative death and the excellent functional results in
terms of patient activity are noted in our series; this trend
likely reflects the strict criteria for patient selection.
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